Neven Henigsberg

List of Publications by Year
in descending order

72	4,730	136950 32	98798 67
papers	citations	h-index	g-index

81	81	81	6046
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. American Journal of Psychiatry, 2014, 171, 1278-1286.	7.2	336
2	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. American Journal of Psychiatry, 2010, 167, 555-564.	7.2	314
3	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine, 2012, 42, 967-980.	4.5	298
4	Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine, 2008, 38, 289-300.	4.5	227
5	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	7.2	216
6	Adverse reactions to antidepressants. British Journal of Psychiatry, 2009, 195, 202-210.	2.8	205
7	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	4.1	202
8	Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2009, 9, 225-233.	2.0	188
9	SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?. Depression and Anxiety, 2012, 29, 1043-1049.	4.1	182
10	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry, 2009, 194, 252-259.	2.8	170
11	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. Journal of Psychiatric Research, 2016, 78, 94-102.	3.1	149
12	Moderation of antidepressant response by the serotonin transporter gene. British Journal of Psychiatry, 2009, 195, 30-38.	2.8	143
13	A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder. Journal of Clinical Psychiatry, 2012, 73, 953-959.	2.2	132
14	Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression. Journal of Clinical Psychiatry, 2011, 72, 1478-1484.	2.2	117
15	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Medicine, 2012, 9, e1001326.	8.4	110
16	Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine, 2010, 40, 1367-1377.	4.5	107
17	Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology, 2009, 34, 2517-2528.	5.4	105
18	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders, 2011, 132, 112-120.	4.1	93

#	Article	IF	Citations
19	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics Journal, 2012, 12, 68-77.	2.0	92
20	Body weight as a predictor of antidepressant efficacy in the GENDEP project. Journal of Affective Disorders, 2009, 118, 147-154.	4.1	89
21	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of Psychopharmacology, 2014, 28, 133-141.	4.0	75
22	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	4.8	71
23	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2011, 11, 138-145.	2.0	70
24	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.7	64
25	Neuroimaging research in posttraumatic stress disorder â€“ Focus on amygdala, hippocampus and prefrontal cortex. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 37-42.	4.8	62
26	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. Scientific Reports, 2018, 8, 5530.	3.3	51
27	Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of Psychopharmacology, 2011, 25, 867-874.	4.0	44
28	Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. BMC Medicine, 2009, 7, 60.	5.5	43
29	Platelet serotonin concentration and suicidal behavior in combat related posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 544-551.	4.8	42
30	Changes in body weight during pharmacological treatment of depression. International Journal of Neuropsychopharmacology, 2011, 14, 367-375.	2.1	41
31	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics Journal, 2018, 18, 413-421.	2.0	40
32	Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of Affective Disorders, 2010, 127, 337-342.	4.1	32
33	Mental Health Consequences in Men Exposed to Sexual Abuse During the War in Croatia and Bosnia. Journal of Interpersonal Violence, 2010, 25, 191-203.	2.0	32
34	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the5-HTTLPR. World Journal of Biological Psychiatry, 2011, 12, 528-538.	2.6	31
35	Dissecting the Genetic Heterogeneity of Depression Through Age at Onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 859-868.	1.7	31
36	Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology, 2015, 232, 2609-2617.	3.1	31

#	Article	IF	Citations
37	Lower Choline-Containing Metabolites/Creatine (Cr) Rise and Failure to Sustain NAA/Cr Levels in the Dorsolateral Prefrontal Cortex Are Associated with Depressive Episode Recurrence under Maintenance Therapy: A Proton Magnetic Resonance Spectroscopy Retrospective Cohort Study. Frontiers in Psychiatry, 2017, 8, 277.	2.6	31
38	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	2.2	31
39	Convergent Animal and Human Evidence Suggests a Role of PPM1A Gene in Response to Antidepressants. Biological Psychiatry, 2011, 69, 360-365.	1.3	30
40	Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological Medicine, 2012, 42, 2027-2035.	4.5	30
41	Association of refractory complex partial seizures with a polymorphism of ApoE genotype. Journal of Cellular and Molecular Medicine, 2005, 9, 698-703.	3.6	28
42	Investigation of blood mRNA biomarkers for suicidality in an independent sample. Translational Psychiatry, 2014, 4, e474-e474.	4.8	24
43	Familiality and SNP heritability of age at onset and episodicity in major depressive disorder. Psychological Medicine, 2015, 45, 2215-2225.	4.5	21
44	Privatization in the health care system of Croatia: effects on general practice accessibility. Health Policy and Planning, 2003, 18, 421-428.	2.7	20
45	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal, 2014, 14, 395-399.	2.0	20
46	A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression. Molecular Psychiatry, 2020, 25, 1312-1322.	7.9	20
47	Transcriptomics and the mechanisms of antidepressant efficacy. European Neuropsychopharmacology, 2016, 26, 105-112.	0.7	19
48	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Translational Psychiatry, 2018, 8, 150.	4.8	19
49	History of suicide attempts among patients with depression in the GENDEP project. Journal of Affective Disorders, 2010, 123, 131-137.	4.1	18
50	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of Psychopharmacology, 2014, 28, 142-150.	4.0	18
51	Stressor characteristics and post-traumatic stress disorder symptom dimensions in war victims. Croatian Medical Journal, 2001, 42, 543-50.	0.7	18
52	Genome-wide association study of co-occurring anxiety in major depression. World Journal of Biological Psychiatry, 2013, 14, 611-621.	2.6	17
53	Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry, 2021, 11, 596.	4.8	15
54	Identification of War Victims in Croatia. Medicine, Science and the Law, 1994, 34, 207-212.	1.0	14

#	Article	IF	Citations
55	Non-random dropout and the relative efficacy of escitalopram and nortriptyline inÂtreating major depressive disorder. Journal of Psychiatric Research, 2012, 46, 1333-1338.	3.1	12
56	War victims in need of physical rehabilitation in Croatia. Scandinavian Journal of Public Health, 1997, 25, 202-206.	0.6	9
57	The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study. Neuropsychiatric Disease and Treatment, 2014, 10, 1243.	2.2	9
58	1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease. Collegium Antropologicum, 2011, 35 Suppl 1, 159-62.	0.2	9
59	Changes in brain metabolites measured with magnetic resonance spectroscopy in antidepressant responders with comorbid major depression and posttraumatic stress disorder. Collegium Antropologicum, 2011, 35 Suppl 1, 145-8.	0.2	8
60	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	7
61	AI-Based Prediction and Prevention of Psychological and Behavioral Changes in Ex-COVID-19 Patients. Frontiers in Psychology, 2021, 12, 782866.	2.1	7
62	Serotonin transporter gene polymorphisms: Relation with platelet serotonin level in patients with primary Sjogren's syndrome. Journal of Neuroimmunology, 2015, 282, 104-109.	2.3	6
63	Evacuation Times of Civilians and Soldiers Wounded during the War in Croatia. Military Medicine, 2006, 171, 1045-1050.	0.8	4
64	Choline and N-acetyl aspartate levels in the dorsolateral prefrontal cortex at the beginning of the recovery phase as markers of increased risk for depressive episode recurrence under different duration of maintenance therapy and after it: a retrospective cohort study. Croatian Medical Journal, 2018, 59, 244-252.	0.7	4
65	Choline elevation in amygdala region at recovery indicates longer survival without depressive episode: a magnetic resonance spectroscopy study. Psychopharmacology, 2021, 238, 1303-1314.	3.1	4
66	Catatonic schizophrenia has a shorter pre-hospitalisation interval than other types of schizophrenia. Journal of Neural Transmission, 2002, 109, 203-212.	2.8	3
67	No change in N-acetyl aspartate in first episode of moderate depression after antidepressant treatment: 1H magnetic spectroscopy study of left amygdala and left dorsolateral prefrontal cortex. Neuropsychiatric Disease and Treatment, 2014, 10, 1753.	2.2	3
68	AUTONOMIC SEIZURES AND DÃ‰JÃ€ VU IN A PATIENT WITH GANGLIOCYTOMA OF THE ORBITOFRONTAL CORTEX. Psychiatria Danubina, 2018, 30, 220-222.	0.4	1
69	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. European Neuropsychopharmacology, 2017, 27, S582-S583.	0.7	0
70	CYP2D6 Revisited in GENDEP: Inter-Platform Concordance. Biological Psychiatry, 2020, 87, S148.	1.3	0
71	PROTON MAGNETIC RESONANCE SPECTROSCOPY IN HUNTINGTON'S DISEASE ACCOMPANYING NEUROBORRELIOSIS. Psychiatria Danubina, 2017, 29, 226-230.	0.4	0
72	Use of non-invasive neuroradiological methods in research of psychoactive drugs. Psychiatria Danubina, 2007, 19, 234-7.	0.4	0